A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs PR 104 (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Proacta
  • Most Recent Events

    • 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Nov 2009 New source identified and integrated (Moores UCSD Cancer Center; 6845)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top